Sodium MRI for Assessment of Early OA.

描述（由申请人提供）：骨关节炎（OA）影响超过5000万美国人，对美国经济和医疗保健系统产生重大影响。目前，这种使人衰弱的疾病还没有治愈的方法，有效的治疗方法充其量是集中在症状缓解上。传统的MR技术已经显示出通过软骨体积或表面颤动来识别更细微的形态学改变的希望。然而，即使这些传统技术更具创新性，在预测膝关节OA进展方面也不一致。因此，对早期识别危险人群的可靠、客观、无创、定量的影像学标志物有很高的需求。该提案的长期目标是开发、实施和表征新型流体抑制3d - 23na - ute技术，用于超高场系统（7T）的体内膝关节应用。软骨的高分辨率、23Na-（聚集蛋白）和1H-（形态学、胶原）成像，以及在超高场系统（7T）上改进的成像脉冲序列、图像重建和可视化方法，将显著影响OA病理的客观评估。具体来说，该提案将建立一个强大的非侵入性成像生物标志物，在临床上对OA疾病严重程度分期、预测进展风险有用，并可能作为OA疾病修饰治疗的未来成像生物标志物。我们将以纵向方式获取年龄和性别匹配的OA受试者的高分辨率钠和质子MRI，以确定基线综合风险概况是否可以预测24个月期间严重膝关节OA进展的风险人群。最后，我们确定了钠和质子联合mri （1h形态学，T2定位和临床评分）在OA受试者基线时的发现在预测膝关节OA进展中的作用。一旦开发出来，在人类膝关节上得到验证，那么钠方法将被转化为临床相关的3T平台。我们相信这些研究不仅会对OA的早期诊断产生深远的影响，还可能对早期识别风险人群产生深远的影响。我们计划通过化学、放射学和风湿病学之间的跨学科合作来实现这些目标，以确定临床有用的风险概况，以预测疾病进展的风险。

DESCRIPTION (provided by applicant): Osteoarthritis (OA) affects over 50 million Americans and has a substantial impact on the US economy and the health care system. Currently, there is no cure for this debilitating disease and the effective treatment is, at best, focused on symptomatic relief. The conventional MR techniques have shown promise for the identification of more subtle morphologic alterations as determined by cartilage volume, or surface fibrillation. However, they even the more innovative of these conventional techniques have not been consistent in predicting the knee OA progression. Therefore, there is a high demand for reliable, objective, non-invasive and quantitative imaging markers that identifies the risk population at early stage. The long-term goal of this proposal is to develop, implement, and characterize novel fluid suppressed-3D-23Na-UTE- techniques for in- vivo knee applications on an ultra high field system (7T). High-resolution, 23Na-(aggrecan) and 1H-(morphology, collagen) imaging of cartilage, along with improved imaging pulse sequences, image reconstructions, and visualization methods on an ultra-high field system (7T) will significantly impact the objective assessment of OA pathology. Specifically, this proposal will establish a powerful non-invasive imaging biomarker that is clinically useful for staging OA disease severity, predicting risk for progression and possibly serving as a future imaging biomarker for disease modifying therapies for OA. We will acquire high resolution sodium and proton MRI of age-and gender matched OA subjects in a longitudinal fashion to determine whether baseline combined risk profile can predict risk population for severe knee OA progression over 24 months period. Finally we determine the role of combined sodium and proton-MRI (1H-morphology, T2 mapping, and clinical scorings) findings at baseline in OA subjects in the prediction of knee OA progression over 24 months period. Once developed, validated in human knee joint then the sodium methodology will be translated on to a clinically relevant 3T platform. We believe that these studies will profoundly affect not only to diagnose OA in its earliest stages but also possibly identifies the risk population at early stage. We plan to address these goals via an interdisciplinary collaboration between Chemistry, Radiology, and Rheumatology to identify a risk profile that will be clinically useful to predict those at risk for disease progression. PUBLIC HEALTH RELEVANCE: Osteoarthritis (OA) affects ~6% of the US adult population and ~12-13% of those age 60 and over. The current proposal will establish a powerful non-invasive imaging biomarker based on a fluid suppressed 3D-23Na- MRI that is clinically useful for assessment of early OA.